Inactive Instrument

News Trillium Therapeutics

Equities

TRIL

CA89620X5064

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

TCR2 Therapeutics Appoints Chief Business and Strategy Officer	22-01-12	MT
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis	21-12-13	DJ
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover	21-12-13	MT
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index	21-11-19	CI
Trillium Therapeutics : Pfizer Completes Acquisition of Trillium Therapeutics - Form 8-K	21-11-17	PU
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition	21-11-17	MT
TRILLIUM THERAPEUTICS INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	21-11-17	AQ
Trillium Therapeutics Inc. Announces Executive Changes	21-11-17	CI
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer	21-11-17	CI
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer	21-11-17	CI
Benchmark Downgrades Trillium Therapeutics to Hold From Buy	21-11-17	MT
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval	21-11-17	MT
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index	21-11-17	CI
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.	21-11-16	CI
TRILLIUM THERAPEUTICS INC. : Other Events (form 8-K)	21-11-16	AQ
Trillium: Q3 Earnings Snapshot	21-11-12	AQ
TRILLIUM THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	21-11-12	AQ
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
North American Morning Briefing : Stock Futures -3-	21-11-05	DJ
Trillium Therapeutics Receives Final Court Order Approving Arrangement - Form 8-K	21-10-29	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Trillium Therapeutics

Equities

TRIL

CA89620X5064

Summary

Filters